
    
      The treatment period is composed of a 24-week double-blind period (week 1-24) and a 28-week
      open-label period (week 25-52). During the double-blind period, participants will receive 10
      mg or 25 mg dose of HSK7653 and matching placebo, or placebo only. During the open-label
      period, all participants will receive 25 mg dose of HSK7653.
    
  